Maria-Luisa Maccecchini (Annovis Bio Inc CEO since 2008) bought $497,000 of stock on the 11th of October at $27.61, increasing her stake by 2%. This is her first stock purchase since a minor subscription for $10,000 at $6 in the January 2020 IPO.
Mark White (Annovis Bio Inc Non-Executive since 2016) bought $137,000 also on the 11th of October, increasing his holding by 10%, again his first purchase since a minor subscription at the IPO.
The shares have been extremely volatile since listing, hitting a peak of $132 before falling back materially on a clinical trial failure; they are still well above the original IPO price. Whilst these are small purchases relative to their holding they are notable large purchases.
We are ranking the stock +N.